Biotech
Mesoblast shares tank after US FDA delays stem cell approval again
The US regulator has again asked for more data on the stem cell treatment maker’s flagship product, which was blocked from approval in 2020 for the same reason.
- by Emma Koehn and Jessica Yun
Latest
How an old Disney movie inspired Daniya to create a medical robot
Whether it’s a medical robot or a high-tech weather station, HSC technology subjects are an opportunity to indulge your passion.
CBD oil and skincare maker has its eye on Australia
Dragonfly Biosciences wants to bring more of its cannabis-based products to local pharmacies.
- by Emma Koehn
Updated
CSL Limited
CSL profits dragged down by currency woes
The biotechnology giant has downgraded its profit guidance after taking a blow from unfavourable currency movements as it competes for plasma donations.
- by Millie Muroi
This cancer-fighting biotech wants to be our next household name
Telix Pharmaceuticals says it has the formula to be a big cash-generating biotech for the long term.
- by Emma Koehn
‘Wake-up call’: China takes stunning lead in race for tech domination
China is the global research leader in 37 of 44 critical technologies, including advanced explosives, biological manufacturing and artificial intelligence.
- by Matthew Knott
Updated
Earnings season
Plasma’s back: Boost for CSL as collections troubles ease
The blood plasma giant reaffirmed full-year guidance on Tuesday, though first-half profits saw a dip.
- by Emma Koehn
‘We deliver’: How CSL shares jumped 367 per cent under this CEO’s reign
After a decade in the top job, CSL boss Paul Perreault weighs in on the future of mRNA, how Australia can secure a biotech boom - and how to choose an AFL team.
- by Emma Koehn
‘Important vaccine for Australia’: Moderna gears up for RSV jab
Moderna will lodge approval applications for a new vaccine for RSV that could be on the market as soon as next year in a big step forward in its pipeline outside of COVID.
- by Emma Koehn
COVID hotshot Ellume saved as rival comes to rescue
Brisbane-based COVID-19 test maker Ellume has been snapped up by rapid test distributor Hough Pharma in a deal worth $57.1 million.
- by Emma Koehn
Updated
CSL Limited
‘Not shy in disrupting ourselves’: Meet CSL’s new boss
The biotech giant’s chief operating officer Paul McKenzie will start in the top job from March after Paul Perreault confirmed he will step down after a mammoth decade at the helm.
- by Emma Koehn